It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

From robot-assisted surgery to personalised disease treatment - technology can do some truly remarkable things. But while the ...

The FDA has called a plan to publish certain complete response letters (CRLs) for medicines it has rejected after an initial ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Technology has also improved immunisation operations with the use of online appointment scheduling that automates ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Greg Piefer, founder and CEO of SHINE Technologies, a ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

Toymaker Mattel has launched its latest addition to the Barbie range of dolls, the first with type 1 diabetes, which comes ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...